#IMNM hashtag - Bluesky

Immunome Reports Full Year 2025 Financial Results and Provides Business Update Immunome, Inc., a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the full year ended December 31, 2025, and provided a business update. “Immunome made substantial progress in 2025. In December 2025, Immunome announced positive topline results from the global...

1 month ago

#IMNM Immunome Reports Full Year 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/IMNM/immunome-repor...

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

3 months ago

Trade Alerts, Wednesday December 17, 2025 – Crystal Equity Research

Small-cap stocks gapping down in trading, Wed Dec 17th - #SNGX #DFSC #VTGN #PLCE #KYTX #IMNM #SPIR - More: crystalequityresearch.com/trade-alerts... - #smallcap

0 0 0 0

Immunome Announces Pricing of Public Offering of Common Stock Immunome, Inc., a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the pricing of an underwritten public offering of 18,625,000 shares of its common stock at a price to the public of $21.50 per share. The gross proceeds to Immunome from the offering, before deducting underwriting...

3 months ago

#IMNM Immunome Announces Pricing of Public Offering of Common Stock

www.stocktitan.net/news/IMNM/immunome-annou...

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

3 months ago

Trade Alerts, Monday December 15, 2025 – Crystal Equity Research

Small-cap stocks gapping up in trading, Mon Dec 15th - #UAG #RADX #MASK #QIPT #KYTX #KVHI #IMNM #ARTV - More: crystalequityresearch.com/trade-alerts... - #smallcap

0 0 0 0

Immunome Announces Proposed Public Offering of Common Stock Immunome (Nasdaq: IMNM) announced a proposed underwritten public offering of $400 million of common stock, with Immunome offering all shares and a 30-day underwriter option to purchase up to an additional $60 million.The offering is subject to market and other conditions and may not be completed as proposed. Joint bookrunning managers are Leerink Partners, J.P. Morgan, TD Cowen, Goldman Sachs & Co. and Guggenheim Securities; co-leads are Wedbush PacGrow and LifeSci Capital. The offering will be made from a Form S-3 shelf registration that became effective on February 13, 2024, and a preliminary prospectus supplement will be filed with the SEC.

3 months ago

#IMNM Immunome Announces Proposed Public Offering of Common Stock

www.stocktitan.net/news/IMNM/immunome-annou...

0 0 0 0

Stock Master

@stockmaster70.bsky.social

3 months ago

📢 Stocks Trending NOW: #IRBT #TSLA #OCG #RADX #MIST #NOW #AMCI #CGC #KYTX #IMNM

0 0 0 0

3 months ago

#IMNM Immunome Announces Positive Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors

www.stocktitan.net/news/IMNM/immunome-annou...

0 0 0 0

3 months ago

NEWS: ( NASDAQ: #IMNM ) Immunome to Announce Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors

0 0 0 0

Immunome to Announce Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors Immunome (Nasdaq: IMNM) will disclose topline results from the global pivotal Phase 3 RINGSIDE trial of varegacestat in patients with progressing desmoid tumors on Monday, December 15, 2025.The company will host a live webcast and conference call on December 15, 2025 at 8:30 a.m. ET (5:30 a.m. PT) that includes presentation slides and a live Q&A following prepared remarks. The webcast is listen-only; questions must be asked via the conference call. The webcast will be archived on Immunome's investor website for 90 days.

3 months ago

#IMNM Immunome to Announce Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors

www.stocktitan.net/news/IMNM/immunome-to-an...

1 0 0 0

4 months ago

#IMNM Immunome Reports Third Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/IMNM/immunome-repor...

0 0 0 0

Immunome Presents Preclinical Data Showing Proprietary TOP1i ADC Payload HC74 Overcomes Multiple Mechanisms of ADC Resistance Immunome (Nasdaq: IMNM) presented preclinical data on Oct. 23, 2025 showing its proprietary ADC payload HC74 overcomes several ADC resistance mechanisms, including payload efflux and target heterogeneity.The poster reported HC74 is a novel topoisomerase I inhibitor used in IM-1021 (a ROR1-targeted ADC in Phase 1) and in multiple preclinical candidates; key findings include high membrane permeability, robust bystander activity, and efficacy in preclinical models refractory or resistant to trastuzumab-DXd, irinotecan, and models with heterogeneous target expression.A copy of the poster is available in the company’s Events & Presentations materials.

5 months ago

#IMNM Immunome Presents Preclinical Data Showing Proprietary TOP1i ADC Payload HC74 Overcomes Multiple Mechanisms of ADC Resistance

www.stocktitan.net/news/IMNM/immunome-prese...

0 0 0 0

Immunome Reports Second Quarter 2025 Financial Results and Provides Business Update Immunome (Nasdaq: IMNM), a biotechnology company developing targeted cancer therapies, reported its Q2 2025 financial results and pipeline updates. The company's cash position of $268.0 million is expected to fund operations into 2027.Key pipeline developments include: varegacestat's upcoming Phase 3 RINGSIDE topline data expected by end of 2025 and recent European Medicines Agency Orphan Drug Designation; IM-1021's ongoing Phase 1 trial reaching its third dose level; and IM-3050's IND clearance with Phase 1 trial initiation planned for late 2025. Three additional preclinical ADCs (IM-1617, IM-1340, and IM-1335) are undergoing IND-enabling work.Q2 2025 financials showed R&D expenses of $40.5 million and G&A expenses of $10.0 million, with a net loss of $43.4 million.

7 months ago

#IMNM Immunome Reports Second Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/IMNM/immunome-repor...

0 0 0 0

9 months ago

Just In: ( NASDAQ: #IMNM ) Trend Tracker for (IMNM)

0 0 0 0

Immunome Reports First Quarter 2025 Financial Results and Provides Business Update Immunome, Inc., a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the quarter ended March 31, 2025 and provided a business update. “Immunome continued to build momentum in the first quarter of 2025,” said Clay B. Siegall, Ph.D., President and Chief Executive Officer.“...

10 months ago

#IMNM Immunome Reports First Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/IMNM/immunome-repor...

0 0 0 0

Alpha Wealth Funds

@alphawealthfunds.bsky.social

1 year ago

Insider Buying 03-28-25 Stagflation is the Game. Confidence has been Shattered The market as measured by the S&P 500 shed 1.53% last month. The dollar was down, gold up. There seems […]

running wild at HHS. Payment reimbursement is uncertain, not to mention the science itself.
Analysis: bit.ly/3FLfPZ9
#InsiderBuying #TheInsidersFund #IMNM #Biotech #MillionDollarBuy

0 0 0 0

The Insiders Fund Hedge Fund Guy

@insomniachedgefund.bsky.social

1 year ago

Insider Buying 03-28-25 Stagflation is the Game. Confidence has been Shattered The market as measured by the S&P 500 shed 1.53% last month. The dollar was down, gold up. There seems […]

The CEO bought a million dollars' worth. That's brave in a world where RFK is running amok at HHS and payment reimbursement is at question, not to mention the science.
Read the full analysis: bit.ly/4ccBV2N
#InsiderBuying #TheInsidersFund #IMNM #Biotech #HealthcareStocks #CEOBuying #RegulatoryRisks

0 0 0 0

Immunome Secures Nearly $400M War Chest as Phase 3 Trial Hits Key Milestone Immunome strengthens financial position with $172.5M raise, extends runway to 2027. Phase 3 RINGSIDE fully enrolled, multiple ADC programs advancing in clinical development.

1 year ago

#IMNM Immunome Reports Full Year 2024 Financial Results and Provides Business Update

www.stocktitan.net/news/IMNM/immunome-repor...

0 0 0 0

Immunome Doses First Patient in Phase 1 Trial of IM-1021, a ROR1-Targeted ADC Immunome (NASDAQ: IMNM) has initiated patient dosing in its Phase 1 clinical trial of IM-1021, a ROR1-targeted ADC (Antibody-Drug Conjugate). The first-in-human trial is designed as an open-label, multicenter study focusing on dose escalation and expansion to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of IM-1021.The study will include patients with advanced B-cell lymphomas and advanced solid tumors. IM-1021 is an optimized ADC incorporating Immunome's proprietary TOP1 inhibitor, HC74, targeting patients with high unmet medical needs.

1 year ago

#IMNM Immunome Doses First Patient in Phase 1 Trial of IM-1021, a ROR1-Targeted ADC

www.stocktitan.net/news/IMNM/immunome-doses...

0 0 0 0

Romain Batton, M.D.

@rbattonmd.bsky.social

1 year ago

Romain Batton on LinkedIn: #ecim2025 #imnm #internalmedicine #myositis This week I have the pleasure and great opportunity to attend to the European Congress of Internal Medicine (#ECIM2025) in Florence, Italy 🇮🇹 . It is…

Another successful day at #ECIM2025 in Florence, Italy ! #posterdiscussion #IMNM #myositis #internalmedicine ☀️

2 0 0 0

Immunome's Massive $150M Capital Raise: Major Banks Back Biotech's Ambitious Plans Immunome secures $150M through 19.35M share offering, backed by JP Morgan and top banks. Additional 2.9M share option available as company strengthens financial position.

1 year ago

#IMNM Immunome Announces Pricing of Upsized Public Offering of Common Stock

www.stocktitan.net/news/IMNM/immunome-annou...

0 0 0 0

Immunome's Massive $125M Capital Raise Could Reshape Cancer Treatment Landscape Leading biotech Immunome launches significant $125M common stock offering, backed by major Wall Street firms, to accelerate development of targeted cancer therapies.

1 year ago

#IMNM Immunome Announces Proposed Public Offering of Common Stock

www.stocktitan.net/news/IMNM/immunome-annou...

0 0 0 0

Immunome Advances Cancer Pipeline: FDA Clears ROR1 ADC Drug, Phase 3 Trial Progress Immunome secures FDA clearance for IM-1021 ADC therapy, advances Phase 3 varegacestat trial, and expands solid tumor pipeline with three novel ADC programs.

1 year ago

#IMNM Immunome Provides Pipeline Update in Advance of Presentation at the 43rd Annual J.P. Morgan Healthcare Conference

www.stocktitan.net/news/IMNM/immunome-provi...

0 0 0 0

1 year ago

Just In: ( NASDAQ: #IMNM ) Immunome to Present at the Piper Sandler 36th Annual Healthcare Conference

#StockMarket #News

1 0 0 0

1 year ago

#IMNM Immunome to Present at the Piper Sandler 36th Annual Healthcare Conference

www.stocktitan.net/news/IMNM/immunome-to-pr...

1 0 0 0

1 year ago

#IMNM Immunome Reports Third Quarter 2024 Financial Results and Provides Business Update

www.stocktitan.net/news/IMNM/immunome-repor...

0 0 0 0

1 year ago

Breaking News: ( NASDAQ: #IMNM ) Immunome Appoints Roee Shahar as Executive Vice President, Commercial

#StockMarket #News

1 0 0 0

1 year ago

JUST IN: ( NASDAQ: #IMNM ) Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

#StockMarket #News

1 0 0 0